# Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

> **NCT05255484** · PHASE1,PHASE2 · TERMINATED · sponsor: **LaNova Medicines Limited** · enrollment: 24 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-108
- **DRUG:** An Anti-PD-1 Antibody

## Key facts

- **NCT ID:** NCT05255484
- **Lead sponsor:** LaNova Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-26
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-10-06
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Completed primary objective.
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255484, "Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05255484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*